– For Professional Investors Only –
Milltrust International is pleased to share an exciting opportunity to co-invest in Attomarker, an early-stage diagnostics company that has invented a new, simple to use, point-of-care blood testing device that can perform multiple tests from a single pinprick of blood.
Recently, Attomarker announced a rapid, seven-minute Triple Antibody Test for COVID-19. The UK regulator MHRA provided approval for the test in July and a partnership with FTSE 100 listed Smiths Group plc was announced to manufacture the test devices.
The patented Attomarker technology uses a disposable credit-card sized chip that slots into a handheld device docked to an iPhone and provides rapid testing for the healthcare professional and the consumer markets.
Alongside its response to COVID-19, Attomarker is continuing its work towards developing tests for fatty liver disease (a precursor of type-2 diabetes), food allergy diagnosis and to distinguish between bacterial and viral infections.
Attomarker are now looking to fund a nationwide roll out of the COVID multiplex antibody test in partnership with a Private Clinic with testing commencing in September to include common influenza strains to be ready for the flu season. We are seeking to extend the last fund raising round to raise 5 million GBP at a pre cash value of 25 million GBP. £1.5m will be used for immediate funding to launch the trial.
View recent article and tv interview with Andrew Shaw below.
For professional investors only. This communication is strictly private and confidential and is meant as guidance and information only. It is issued by Milltrust International LLP incorporated in the United Kingdom, which is authorised and regulated by the Financial Conduct Authority. Milltrust International LLP has its registered office at 5 Market Yard Mews, 194-204 Bermondsey Street, London, SE1 3TQ, United Kingdom and is a subsidiary of Milltrust International Group (Singapore) Pte Ltd. Milltrust Agricultural Investments Ltd is an affiliate of Milltrust International LLP. The content in this document is for informational purposes only and does not constitute legal, tax, investment, financial, or other advice. Nothing contained in this document constitutes a solicitation, recommendation, endorsement, or offer by Milltrust International LLP or any of its affiliates to buy or sell any securities or other financial instruments. No such solicitation or offer is made in this or in any other jurisdiction in which such solicitation or offer would be unlawful under the securities laws of such jurisdiction. All content in this document is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in the document constitutes professional and/or financial advice, nor does any information on the document constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. It should therefore not be used as the sole basis for any investment or other decision. The use of or access to this document or content by any person does not create a fiduciary relationship between such person and Milltrust International LLP. The sole responsibility of evaluating the merits and risks associated with the use of any information or other content on this communication before making any decisions based on such information or other content rests with the user and their professional advisers.